Q32 Bio and Horizon partner to develop autoimmune disease treatment
Pharmaceutical Technology
AUGUST 16, 2022
antibody, ADX-914 re-regulates adaptive immune function by hindering IL-7 and TSLP-facilitated signalling. On Horizon exercising the option, Q32 could be entitled to further receive up to another $645m in closing and milestone payments. Q32 will also receive tiered royalty payments on net sales. A fully human anti-IL-7R?
Let's personalize your content